Influvac

Influenza Virus B/Austria/1359417/2021‑Like Strain (B/Austria/1359417/2021, Bvr‑26) and Influenza A/Vic, the active ingredient in Influvac, is a vaccine presented as a standard dose injectable solution for intramuscular or subcutaneous use. It stimulates the immune system to produce antibodies that protect adults and children against seasonal influenza caused by influenza A and B viruses.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care institutions worldwide, with a focus on timely delivery, regulatory compliance and cold‑chain logistics for vaccine products.

Influvac is an inactivated influenza vaccine indicated for the prevention of influenza caused by influenza A and B viruses. - Seasonal influenza (A and B): provides protection against circulating strains, reducing the risk of infection and associated complications. - Elderly and individuals with chronic conditions: lowers incidence of severe influenza disease and hospitalisation. - Children 6 months to 5 years: supports immune protection during the flu season. - Pregnant women: helps prevent influenza‑related morbidity for mother and fetus. - Healthcare workers: reduces transmission risk in clinical settings.

Influvac, like other inactivated influenza vaccines, may be associated with local and systemic reactions following injection.

Common Side Effects: - Injection site pain: mild to moderate soreness at the injection site. - Redness or swelling: transient erythema or edema around the site. - Low‑grade fever: temperature up to 38 °C within 24 hours. - Headache: mild headache occurring shortly after vaccination. - Myalgia: muscle aches lasting one to two days. - High fever: temperature above 39 °C, may need antipyretics. - Severe local reaction: extensive swelling or necrosis.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may develop within weeks. - Seizures: infrequent occurrence, especially in children with fever. - Severe allergic reaction: includes angioedema or bronchospasm. - Persistent high fever: prolonged temperature elevation beyond 48 hours.

Before administering Influvac, healthcare professionals should observe the following precautions to ensure safe use. - Allergy assessment: avoid vaccination in individuals with known hypersensitivity to any vaccine component. - Acute illness: postpone vaccination if the person has moderate or severe fever or acute infection. - Pregnancy: consult a healthcare provider; safety data are limited, use only if benefits outweigh risks. - Immunocompromised patients: vaccine may be less effective; monitor immune response. - Concomitant medications: avoid simultaneous administration of immunoglobulins or blood products that could interfere with antibody development. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac may interact with certain agents that affect immune response or mask vaccine‑related symptoms.

Major Interactions (Avoid): - Immunoglobulin therapy: may reduce vaccine‑induced antibody production. - Live attenuated vaccines: avoid co‑administration within 4 weeks to prevent interference.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may alleviate fever but could blunt antibody response if taken prophylactically. - Immunosuppressive drugs (corticosteroids, chemotherapy): may diminish vaccine efficacy. - Antiviral agents (oseltamivir) given within 48 hours of vaccination: may interfere with immune response.